// App-Quantinova.ai

1243 : Longer recurrence free survival (RFS) in germline pathogenic variant (gPV) positive patients with melanoma on adjuvant checkpoint immunotherapy (IO)

Researchers

Presenter

  • A. Shen

Principal Investigators

  • M. Arbesman

  • R. Lodha

  • N. Buturla

  • M. Diaz

  • P. Funchain

  • J. Arbesman

Medical Centers

  • Cleveland Clinic, Cleveland, United States,

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Lynch syndrome

  • Melanoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved